Talat Ayyildiz

Talat Ayyildiz

Auto-generated profile, based on publicly available information

Talat Ayyildiz

Department of Gastroenterology, Ondokuz Mayıs University, Samsun, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2021 in Journal of Experimental and Clinical Medicine
Verified
Journal Article
Closed access
BBBerk Baş
Berk Baş
TATalat Ayyildiz
Talat Ayyildiz
UAUFUK AVCIOGLU
UFUK AVCIOGLU
Upper and lower gastrointestinal bleeding is a medical problem that is encountered in the clinic quite often. Endoscopic procedures still constitute the basis of the treatment in gastrointestinal bleeding. Hemoclips, argon plasma coagulation, sclerotherapy, heater probe, and hemosprays accompanied by endoscopy are used alone or in combination. In this study, we shared our experience of using the drug called Ankaferd blood stopper, which is indicated for use in many forms of bleeding, in 64 patients who applied to our clinic with upper or lower gastrointestinal bleeding between January 2019 and April 2020.

1 January 2023 in Hepatology Forum
Verified
Journal Article
Open access
SYSerkan Yaras
Serkan Yaras
MDMehmet Demir
Mehmet Demir
SBSezgin Barutcu
Sezgin Barutcu
AYAbdullah Emre Yıldırım
Abdullah Emre Yıldırım
SGSelim Gurel
Selim Gurel
RIRamazan Idilman
Ramazan Idilman
Background and Aim: The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). Materials and Methods: Between May 2019 and May 2022, 686 patients with CHC, treated with GLE/PIB combination from 21 participating centers in Turkiye, were enrolled in the study. Results: All patients were Caucasian, and their median age was 56 years. At the start of GLE/PIB treatment, the median serum Hepatitis C virus RNA and serum alanine amino transaminase (ALT) levels were 6.74 log10 IU/mL and 47 U/L, respectively. Fifty-three percent of the patients were infected with genotype 1b, followed by genotype 3 (17%). Diabetes was the more common concomitant disease. The sustained virological response (SVR12) was 91.4% with intent-to-treat analysis and 98.5% with per proto-col analysis. The SVR12 rates were statistically significant differences be-tween the patients who were i.v. drug users and non-user (88.0% vs. 98.8%,p=0.025). From the baseline to SVR12, the serum ALT levels and Model for End-Stage Liver Disease score were significantly improved (p

1 January 2026 in Hepatology Forum
Verified
Journal Article
Closed access
UAUFUK AVCIOGLU
UFUK AVCIOGLU
HDHakan Demiröz
Hakan Demiröz
ASAysegul Idil Soylu
Aysegul Idil Soylu
FUFatih Uzunkaya
Fatih Uzunkaya
HAHüseyin Akkaya
Hüseyin Akkaya
ABAhmet Bektaş
Ahmet Bektaş
Background and Aim: To evaluate the diagnostic performance, technical feasibility, and safety of percutaneous endobiliary punch biopsy (PEPB) in patients with suspected malignant biliary strictures, particularly when endoscopic approaches are not feasible. Materials and Methods: This retrospective, single-center study included 23 patients with radiologically confirmed biliary strictures who underwent PEPB between January 2020 and January 2025. All procedures were conducted under fluoroscopic guidance following percutaneous biliary drainage. Clinical, laboratory, and procedural data were reviewed. Results: Biopsy samples were adequate for histopathological analysis in all cases. The technical success rate was 100%. Malignancy was diagnosed in 17 patients (73.9%), while 3 cases were benign and 3 were false negatives later confirmed as malignant. The sensitivity and specificity of PEPB were 86.96% and 100%, respectively. Two minor complications (8.7%)—cholangitis and hematoma—occurred and were managed conservatively. Conclusion: PEPB is a safe, technically viable, and diagnostically accurate method for tissue sampling in biliary strictures. It offers a valuable alternative when endoscopic biopsy fails or is not feasible.

1 January 2022 in Diagnostic and Interventional Endoscopy
Verified
Journal Article
Closed access
BYBeytullah Yıldırım
Beytullah Yıldırım
YKYusuf Bünyamin Ketenci
Yusuf Bünyamin Ketenci
UAUFUK AVCIOGLU
UFUK AVCIOGLU
IGİbRahim Gören
İbRahim Gören
TATalat Ayyıldız
Talat Ayyıldız
ABAhmet Bektaş
Ahmet Bektaş
Objective: Proton pump inhibitors may alter intestinal microbiota, and changes in intestinal microbiota may lead to the activation of inflammatory bowel disease. In our study, we investigated the association between proton pump inhibitor use and inflammatory bowel disease activation. Methods: A total of 67 inflammatory bowel disease patients were enrolled in this study. The number of inflammatory bowel disease episodes, medications used, and the use of proton pump inhibitors were evaluated retrospectively for all patients. We divided the patients into 2 groups as proton pump inhibitor users and non-proton pump inhibitor users, and the groups were compared. Results: The median age of the 67 inflammatory bowel disease patients (41 male and 26 female) was 37 (18-70) years. The disease duration since diagnosis was 63.4 (10.2-223.6) months, and the total number of episodes was 3.0 (0-20). Crohn’s disease was diagnosed in 23 patients (34.3%) and ulcerative colitis in 44 (65.7%) patients. Of the patients, 35 (52.2%) were on anti-tumor necrosis factor treatment and 41 (61.2%) had proton pump inhibitor usage history for a median of 40 (1-300) months. Among 41 proton pump inhibitor users, 34 (82.9%) had a history of inflammatory bowel disease activation during the course of treatment. When proton pump inhibitor users and non-proton pump inhibitor users were compared in terms of disease duration, there was no difference (P=.65); however, the number of inflammatory bowel disease episodes was significantly different (5.0 (0-20) episodes vs. 1.5 (0-17) episodes, respectively; P < .0001). Conclusion: In patients with inflammatory bowel disease, proton pump inhibitor use may be associated with an increase in the incidence of disease episodes. Randomized, controlled studies involving more patients will guide to clarify the uncertain points of this finding.

18 March 2021 in Journal of Experimental and Clinical Medicine
Verified
Journal Article
Closed access
TATalat Ayyildiz
Talat Ayyildiz
MDMustafa Emre Duygulu
Mustafa Emre Duygulu
Upper gastrointestinal bleeding (UGIB) is a common, life-threatening medical condition. Non-variceal causes account for more than 90% of bleeding episodes. Peptic ulcer disease is the most frequent cause of non-variceal UGIB. Patients present with hematemesis and/or melena but hematochezia might be present in patients with severe bleeding. Despite advances in diagnostic and therapeutic methods, mortality remains high in the elderly and patients with comorbidities. Endoscopy is the primary procedure that should be performed to identify the etiology of UGIB and for treatment purposes following adequate resuscitation of patients. Early endoscopy (within the first 24 hours) has considerably improved the clinical outcomes. A number of scoring systems are being used in patients with UGIB to identify the risk of complications, rebleeding risk, the need for interventional procedures and the risk of death. The most commonly used scoring tools are the Rockall score, Glasgow-Blatchford score and AIMS65 score. Primary treatment modalities include adequate resuscitation, intravenous fluid support, transfusion of red blood cell suspension, acid suppression therapy and administration of prokinetic agents. In general, angiography, computed tomography, technetium-99m-labeled red blood cell scintigraphy and capsule endoscopy may be used in patients whose bleeding cannot be detected endoscopically. Interventional radiological procedures should be initially performed for hemorrhages that cannot be stopped endoscopically and surgical options should be considered when interventional radiological procedures are out of reach or unsuccessful.

18 March 2021 in Journal of Experimental and Clinical Medicine
Verified
Journal Article
Closed access
TŞTuğba ŞENEL
Tuğba ŞENEL
TATalat Ayyildiz
Talat Ayyildiz
Clostridium difficile infection (CDI) is an important health problem with severe morbidity and mortality. In our study, 266 adult patients admitted to the hospital between the years 2005 and 2020, and were diagnosed with CDI were included. The relationship between CDI and fecal occult blood test (FOBT) was examined, and it was aimed to determine the clinical characteristics of CDI patients and risk factors for mortality and recurrence in these patients. FOBT was found to be positive in 42.8% of our CDE patients who had occult blood in stool. Pseudomembranous enterocolitis (PME) developed in 2.2% of our patients and toxic megacolon developed in 0.8%; while 10.2% of the patients had a mortal course within 30 days and 5.2% of them had a recurrence. In our study, a significant relationship was found between mortality and advanced age, negativity of FOBT, presence of hospitalization history, and also between FOBT positivity and the presence of PME and recurrence. We believe that the data documented in this study are important because it both reveal the clinical characteristics of CDI patients and its relationship with FOBT.